Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heidelberg Pharma AG (WL6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012203
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small molecules and antibodies, which are offered for out-licensing. Wilex’s pipeline products are focused at treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Heidelberg Pharma GmbH (Heidelberg), Wilex’s subsidiary provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg focuses on the development of a proprietary ADC technology. Heidelberg Pharma is headquartered in Munich, Germany.

Heidelberg Pharma AG (WL6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Licensing Agreements 18
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Equity Offering 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Acquisition 35
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG – Key Competitors 37
Heidelberg Pharma AG – Key Employees 38
Heidelberg Pharma AG – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Jul 13, 2017: WILEX reports on first half-year 40
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 42
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 44
Jul 14, 2016: WILEX publishes Half-yearly Financial Report 46
Apr 14, 2016: WILEX AG: Interim management statement on the first quarter of 2016 48
Mar 22, 2016: WILEX announces financial figures for the 2015 financial year and reports on course of business 51
Corporate Communications 53
Jun 02, 2016: WILEX announces change on the Executive Management Board 53
Apr 06, 2016: WILEX plans change on the Supervisory Board 54
Product News 55
03/01/2016: RedHill Biopharma Provides Update on MESUPRON 55
Product Approvals 56
Jan 13, 2016: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON in China 56
Other Significant Developments 57
Oct 13, 2016: WILEX: Interim Management Statement on the First Nine Months of 2016 57
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG, Key Competitors 37
Heidelberg Pharma AG, Key Employees 38
Heidelberg Pharma AG, Subsidiaries 39

★海外企業調査レポート[Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Clorox Company:戦略・SWOT・企業財務分析
    The Clorox Company - Strategy, SWOT and Corporate Finance Report Summary The Clorox Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Continental AG:企業の戦略・SWOT・財務情報
    Continental AG - Strategy, SWOT and Corporate Finance Report Summary Continental AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • DKSH Holding Ltd (DKSH):企業の財務・戦略的SWOT分析
    DKSH Holding Ltd (DKSH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • SpectraCure AB (SPEC)-製薬・医療分野:企業M&A・提携分析
    Summary SpectraCure AB (SpectraCure) is a healthcare technology company that develops different methods for treatment planning and laser light dose management for cancer treatment. The company develops and therapy system (PDT) commercializes photodynamic with IDOSE for tumors. Its IDOSE platform all …
  • Blackbird Plc (BIRD):企業の財務・戦略的SWOT分析
    Summary Blackbird plc (Blackbird), formerly Forbidden Technologies plc, is a technology company that develops and commercializes cloud-based video technology. The company offers products such as FORscene- cloud-based post-production platform, captevate- online video editor and eva-video social netwo …
  • Global Dominion Access SA:企業の戦略・SWOT・財務分析
    Global Dominion Access SA - Strategy, SWOT and Corporate Finance Report Summary Global Dominion Access SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Zenrosai:企業の戦略・SWOT・財務情報
    Zenrosai - Strategy, SWOT and Corporate Finance Report Summary Zenrosai - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Oncopeptides AB (ONCO):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncopeptides AB (Oncopeptides) is a clinical development pharmaceutical company that offers development of oncology therapies to treat multiple myeloma. The company’s lead product candidate Ygalo (melflufen) is a peptidase potentiated cytotoxic drug and a potent anti-angiogenetic compound, a …
  • TransMontaigne Product Services LLC:企業の戦略・SWOT・財務情報
    TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report Summary TransMontaigne Product Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • ACWA Power International:電力:M&Aディール及び事業提携情報
    Summary ACWA Power International (ACWA Power), a subsidiary of ACWA Holding is a power generation company that develops and operates power generation and desalinated water production plants. The company holds a generation portfolio of power and desalinated water. Its projects comprise in selecting i …
  • RattanIndia Power Ltd (RTNPOWER):電力:M&Aディール及び事業提携情報
    Summary RattanIndia Power Ltd (RattanIndia Power), formerly Sophia Power Company Ltd is a power company that constructs, develops, operates, and manages thermal power projects across India. The company offers renewable energy solutions, operation and management of power plants, and project managemen …
  • KARL STORZ GmbH & Co KG-医療機器分野:企業M&A・提携分析
    Summary KARL STORZ GmbH & Co KG (Karl Storz) is a manufacturer and distributor of endoscopes, surgical devices and medical instruments. The company offers rigid and flexible endoscopes, instruments for the field of human medicine used for neurosurgery; oral and maxillofacial surgery; ear, nose, and …
  • Hachsharat Hayishuv Hotels Ltd.:企業の戦略・SWOT・財務分析
    Hachsharat Hayishuv Hotels Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hachsharat Hayishuv Hotels Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Brunswick Corporation (BC):企業の財務・戦略的SWOT分析
    Brunswick Corporation (BC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Lukoil Oil Co (LKOH):石油・ガス:M&Aディール及び事業提携情報
    Summary Lukoil Oil Co (Lukoil) is a vertically integrated oil and gas company, which carries out exploration and production of crude oil and natural gas. Lukoil has interest in properties across Russia, Kazakhstan, Azerbaijan, Uzbekistan, the Middle East, South America, Northern and Western Africa a …
  • Westinghouse Electric Company LLC:電力:M&Aディール及び事業提携情報
    Summary Westinghouse Electric Company, LLC (Westinghouse) a subsidiary of Toshiba Corporation, is a nuclear energy company. It offers nuclear plant products, technologies, nuclear fuel, plant design and related services to utilities across the world. The company conducts the development, licensing, …
  • Komatsu Ltd.:企業の戦略・SWOT・財務情報
    Komatsu Ltd. - Strategy, SWOT and Corporate Finance Report Summary Komatsu Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Air Mauritius Ltd.:企業の戦略・SWOT・財務情報
    Air Mauritius Ltd. - Strategy, SWOT and Corporate Finance Report Summary Air Mauritius Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Timken Company
    The Timken Company - Strategy, SWOT and Corporate Finance Report Summary The Timken Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Gree Electric Appliances, Inc. of Zhuhai:戦略・SWOT・企業財務分析
    Gree Electric Appliances, Inc. of Zhuhai - Strategy, SWOT and Corporate Finance Report Summary Gree Electric Appliances, Inc. of Zhuhai - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆